VE303

Vedanta Raises $106.5M to Advance New Class of C.diff Therapeutics
BioSpace
Tue, 04/25/23 - 10:00 pm
Vedanta Biosciences
funding
C. difficile
VE303
Microbiome upstart Vedanta gets an extra $18.5M in the bank, wrapping up $45.5 series C round
Endpoints
Mon, 05/13/19 - 10:03 am
microbiome
Vedanta Biosciences
VE303
Clostridium Difficile